These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28881779)

  • 1. The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer.
    Wang L; Yu X; Wang C; Pan S; Liang B; Zhang Y; Chong X; Meng Y; Dong J; Zhao Y; Yang Y; Wang H; Gao J; Wei H; Zhao J; Wang H; Hu C; Xiao W; Li B
    Oncotarget; 2017 Aug; 8(32):52877-52888. PubMed ID: 28881779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined SRC inhibitor saracatinib and anti-ErbB2 antibody H2-18 produces a synergistic antitumor effect on trastuzumab-resistant breast cancer.
    Wang L; Yu X; Dong J; Meng Y; Yang Y; Wang H; Wang C; Zhang Y; Zhao Y; Zhao J; Wang H; Lu C; Li B
    Biochem Biophys Res Commun; 2016 Oct; 479(3):563-570. PubMed ID: 27666484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic antitumor effect of the anti-ErbB2 antibodies trastuzumab and H2-18 on trastuzumab-resistant gastric cancer cells.
    Wang C; Wang L; Liang B; Zhou B; Sun Y; Meng Y; Dong J; Chen L; Li B
    Oncol Lett; 2021 May; 21(5):400. PubMed ID: 33777223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An anti-ErbB2 fully human antibody circumvents trastuzumab resistance.
    Lu Q; Wang L; Zhang Y; Yu X; Wang C; Wang H; Yang Y; Chong X; Xia T; Meng Y; Wang Y; Lu C; Zhou L; Li B
    Oncotarget; 2016 Oct; 7(41):67129-67141. PubMed ID: 27564098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody.
    Wang C; Wang L; Yu X; Zhang Y; Meng Y; Wang H; Yang Y; Gao J; Wei H; Zhao J; Lu C; Chen H; Sun Y; Li B
    Oncotarget; 2017 Jun; 8(26):42742-42751. PubMed ID: 28514745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
    Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
    Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization.
    Li B; Meng Y; Zheng L; Zhang X; Tong Q; Tan W; Hu S; Li H; Chen Y; Song J; Zhang G; Zhao L; Zhang D; Hou S; Qian W; Guo Y
    Cancer Res; 2013 Nov; 73(21):6471-83. PubMed ID: 24046294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A tipping-point for apoptosis following dual inhibition of HER2 signaling network by T-DM1 plus GDC-0980 maximizes anti-tumor efficacy.
    Dey N; Aske J; Lin X; Sun Y; Leyland-Jones B; Friedman L; De P
    Am J Cancer Res; 2021; 11(6):2867-2892. PubMed ID: 34249433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
    Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bispecific anti-ErbB2 antibody potently induces ErbB2 internalization and suppresses ErbB2-overexpressing tumor growth.
    Zhang Y; Wang L; Chong X; Yu X; Meng Y; Dong J; Wang C; Wang H; Yang Y; Xia T; Zhao J; Li B
    Biochem Biophys Res Commun; 2016 Sep; 477(4):755-760. PubMed ID: 27363335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A PI3K p110α-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice.
    Choi JH; Kim KH; Roh KH; Jung H; Lee A; Lee JY; Song JY; Park SJ; Kim I; Lee WS; Seo SK; Choi IW; Fu YX; Yea SS; Park S
    Oncoimmunology; 2018; 7(5):e1421890. PubMed ID: 29721370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
    Kim WE; Serrero G
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4192-9. PubMed ID: 16857791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
    Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
    J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.
    Kirouac DC; Du JY; Lahdenranta J; Overland R; Yarar D; Paragas V; Pace E; McDonagh CF; Nielsen UB; Onsum MD
    Sci Signal; 2013 Aug; 6(288):ra68. PubMed ID: 23943608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab.
    Cavalloni G; Sarotto I; Pignochino Y; Gammaitoni L; Migliardi G; Sgro L; Piacibello W; Risio M; Aglietta M; Leone F
    Anticancer Drugs; 2008 Aug; 19(7):689-96. PubMed ID: 18594210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors.
    Meng Y; Zheng L; Yang Y; Wang H; Dong J; Wang C; Zhang Y; Yu X; Wang L; Xia T; Zhang D; Guo Y; Li B
    Oncogenesis; 2016 Mar; 5(3):e211. PubMed ID: 26999718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells.
    Fujita T; Doihara H; Washio K; Kawasaki K; Takabatake D; Takahashi H; Tsukuda K; Ogasawara Y; Shimizu N
    Anticancer Drugs; 2006 Apr; 17(4):455-62. PubMed ID: 16550004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo.
    Wallin JJ; Guan J; Prior WW; Lee LB; Berry L; Belmont LD; Koeppen H; Belvin M; Friedman LS; Sampath D
    Clin Cancer Res; 2012 Jul; 18(14):3901-11. PubMed ID: 22586300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
    Xia W; Husain I; Liu L; Bacus S; Saini S; Spohn J; Pry K; Westlund R; Stein SH; Spector NL
    Cancer Res; 2007 Feb; 67(3):1170-5. PubMed ID: 17283152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.